Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts.

Tsou PS, Talia NN, Pinney AJ, Kendzicky A, Piera-Velazquez S, Jimenez SA, Seibold JR, Phillips K, Koch AE.

Arthritis Rheum. 2012 Jun;64(6):1978-89. doi: 10.1002/art.34336. Epub 2011 Dec 12.

2.

Lipoic acid plays a role in scleroderma: insights obtained from scleroderma dermal fibroblasts.

Tsou PS, Balogh B, Pinney AJ, Zakhem G, Lozier A, Amin MA, Stinson WA, Schiopu E, Khanna D, Fox DA, Koch AE.

Arthritis Res Ther. 2014;16(5):411.

3.
4.

Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate.

Dooley A, Shi-Wen X, Aden N, Tranah T, Desai N, Denton CP, Abraham DJ, Bruckdorfer R.

Rheumatology (Oxford). 2010 Nov;49(11):2024-36. doi: 10.1093/rheumatology/keq208. Epub 2010 Jul 13.

PMID:
20627968
5.

MicroRNA-29, a key regulator of collagen expression in systemic sclerosis.

Maurer B, Stanczyk J, Jüngel A, Akhmetshina A, Trenkmann M, Brock M, Kowal-Bielecka O, Gay RE, Michel BA, Distler JH, Gay S, Distler O.

Arthritis Rheum. 2010 Jun;62(6):1733-43. doi: 10.1002/art.27443.

6.

A reactive oxygen species-mediated loop maintains increased expression of NADPH oxidases 2 and 4 in skin fibroblasts from patients with systemic sclerosis.

Spadoni T, Svegliati Baroni S, Amico D, Albani L, Moroncini G, Avvedimento EV, Gabrielli A.

Arthritis Rheumatol. 2015 Jun;67(6):1611-22. doi: 10.1002/art.39084.

7.

RNA interference against platelet-derived growth factor receptor α mRNA inhibits fibroblast transdifferentiation in skin lesions of patients with systemic sclerosis.

Liu T, Zhang J, Zhang J, Mu X, Su H, Hu X, Liu W, Zhao E, Li W.

PLoS One. 2013;8(4):e60414. doi: 10.1371/journal.pone.0060414. Epub 2013 Apr 5.

8.

Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis.

Distler O, Pap T, Kowal-Bielecka O, Meyringer R, Guiducci S, Landthaler M, Schölmerich J, Michel BA, Gay RE, Matucci-Cerinic M, Gay S, Müller-Ladner U.

Arthritis Rheum. 2001 Nov;44(11):2665-78.

PMID:
11710722
9.

Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis.

Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A.

N Engl J Med. 2006 Jun 22;354(25):2667-76.

10.
11.

Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors.

Kawaguchi Y, Takagi K, Hara M, Fukasawa C, Sugiura T, Nishimagi E, Harigai M, Kamatani N.

Arthritis Rheum. 2004 Jan;50(1):216-26.

12.

Increased expression of NAPDH oxidase 4 in systemic sclerosis dermal fibroblasts: regulation by transforming growth factor β.

Piera-Velazquez S, Makul A, Jiménez SA.

Arthritis Rheumatol. 2015 Oct;67(10):2749-58. doi: 10.1002/art.39242.

13.

The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.

Avouac J, Palumbo-Zerr K, Ruzehaji N, Tomcik M, Zerr P, Dees C, Distler A, Beyer C, Schneider H, Distler O, Schett G, Allanore Y, Distler JH.

Arthritis Rheumatol. 2014 Nov;66(11):3140-50. doi: 10.1002/art.38819.

14.
15.

Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.

Akamata K, Asano Y, Aozasa N, Noda S, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Sato S.

Arthritis Res Ther. 2014 Apr 3;16(2):R86. doi: 10.1186/ar4529.

16.
17.

Role of endothelin-1 in the skin fibrosis of systemic sclerosis.

Jing J, Dou TT, Yang JQ, Chen XB, Cao HL, Min M, Cai SQ, Zheng M, Man XY.

Eur Cytokine Netw. 2015 Jan-Mar;26(1):10-4. doi: 10.1684/ecn.2015.0360.

18.
19.

Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts.

Brembilla NC, Montanari E, Truchetet ME, Raschi E, Meroni P, Chizzolini C.

Arthritis Res Ther. 2013 Oct 10;15(5):R151. doi: 10.1186/ar4334.

20.

Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab.

Fraticelli P, De Vita S, Franzolini N, Svegliati S, Scott CA, Tonnini C, Spadoni T, Gabrielli B, Pomponio G, Moroncini G, Gabrielli A.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S160-7. Epub 2015 Sep 1.

PMID:
26339895

Supplemental Content

Support Center